文章核心观点 - 盈收预期修正对股票短期价格走势影响大，Zacks评级系统利用这一力量对股票评级，Vincerx Pharma评级升至Zacks Rank 2，暗示近期股价可能上涨 [2][3][14] 分组1：Zacks评级系统 - Zacks评级核心是公司盈收情况变化，跟踪当前和下一年的Zacks共识预期 [1] - Zacks Rank股票评级系统用四个与盈收预期相关因素将股票分为五组，自1988年以来Zacks Rank 1股票年均回报率达+25% [4] - Zacks评级系统对超4000只股票维持“买入”和“卖出”评级比例相等，仅前5%获“强力买入”评级，接下来15%获“买入”评级 [12] 分组2：Vincerx Pharma情况 - 分析师不断上调Vincerx Pharma预期，过去三个月Zacks共识预期提高27.1% [5] - Vincerx Pharma评级升至Zacks Rank 2，反映盈收预期上升趋势，暗示公司基本面业务改善 [6][9] - 预计截至2024年12月财年公司每股收益为 -$0.74，同比变化60.9% [11] - Vincerx Pharma升至Zacks Rank 2使其在盈收预期修正方面处Zacks覆盖股票前20%，暗示近期股价可能上涨 [14] 分组3：盈收预期与股价关系 - 公司未来盈收潜力变化与股票短期价格走势强相关，机构投资者根据盈收和盈收预期计算股票公允价值并买卖，导致股价变动 [3] - 实证研究表明盈收预期修正趋势与股票短期走势强相关，跟踪此类修正用于投资决策可能有回报 [10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-3197402 (State o ...

Exhibit 99.1 Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti- CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive results from enitociclib Phase 1 combination study, reporting a fourth partial response (PR) in a patient with peripheral T-cel ...

Exhibit 99.1 VersAptx™ Platform Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial ongoing for VIP943, a best-in-class anti-CD123 antibody-drug conjugate (ADC); preliminary data anticipated on or around the 2024 European Hematology Association (EHA) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-3197402 (State or Oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-3197402 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-3197402 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 260 Sheri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-3197402 (State or Oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-3197402 (Sta ...